Abstract
Chimeric vasopressin V2/OT receptors were constructed and investigated to identify receptor regions involved in ligand binding or G protein coupling. The fusion sites for one series of hybrid receptors were either located at the C-terminal end of the third extracellular domain or in the centre of the third transmembrane helix, respectively. In each pair of the resulting symmetrical hybrids only one receptor was able to bind arginine vasopressin (AVP) and/or oxytocin (OT). In both cases a major part of the vasopressin V2, receptor (V2R) was needed for ligand binding. A chimeric OT/V2 receptor including Of receptor (OTR) sequences from its N-terminus to the middle of transmembrane region three showed both high-affinity OT binding (K i = 3 nM) and activation of the adenylyl cyclase. In contrast, a hybrid containing OTR sequences reaching from transmembrane helix five to its C-terminus showed the V2 receptors ligand binding profile and was unable to couple to Gαs. These results indicate (i) that the third and/or the fourth intracellular domain of the V2R are involved in G protein coupling and (ii) for high-affinity OT binding the N-terminal third of the OTR plays an important role.
By detailed binding studies on a second series of chimeric V2/OT receptors with AVP, OT and the two hybrid hormone derivatives arginine vasotocin and oxypressin it was further demonstrated that the first two extracellular domains of the OTR are involved in binding to the C-terminal tripeptide of OT. Moreover, the third extracellular domain of the OTR is able to contact the cyclic part of OT and the fourth outer domain does not interact with the two variable amino acid residues of AVP and OT. Thus, the first three extracellular domains of the OTR provide an essential part of the OT binding site. The other part is most probably contributed by the OTRs transmembrane helices 3 and 4.
Photoaffinity labeling and ligand binding studies demonstrated that the binding site for the OT antagonist d(CH2)5[Tyr(Me)2, Thr4, Orn8, Tyr9]vasotocin is located in the helices 1, 2 and 7. Our results provide evidence for the existence of separate domains of a peptide hormone receptor involved in binding and selectivity for agonists and peptide antagonists.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bathgate R, Rust W, Balvers M, Hartung S, Morley S, Ivell R 1995 The structure and expression of the bovine oxytocin receptor gene. DNA and Cell Biology 14:1045–1056
Gorbulev V, Büchner H, Akhundova A, Fahrenholz F 1993 Molecular cloning and functional characterization of V, [8-lysine] vasopressin and oxytocin receptors from a pig kidney cell line. Eur J Biochem 215:1–7
Kimura T, Tanizawa O, Mori K, Brownstein MJ, Okayama H 1992 Structure and expression of a human oxytocin receptor. Nature 356:526–529
Riley RP, Flint APF, Abayasekara DRE, Stewart Hi 1995 Structure and expression of an ovine endometrial oxytocin receptor cDNA. J Mol Endocrin 15:195–202
Rozen F, Russo C, Banville D, Zingg H 1995 Structure, characterisation and expression of the rat oxytocin receptor gene. Proc Natl Acad Sci USA 92:200–204
Birnbaumer M, Seibold A, Gilbert S, Ishido M, Barberis C, Antaramian A, Brabet P, Rosenthal W 1992 Molecular cloning of the receptorfor human antidiuretic hormone. Nature 357:333–335
Lolait SJ, O’Carroll A-M, McBride OW, Konig M, Morel A, Brownstein MJ 1992 Cloning and characterization of a vasopressin V, receptor and possible link to nephrogenic diabetes insipidus. Nature 357:336–339
Ufer E, Postina R. Gorbulev V, Fahrenholz F 1995 An extracellular residue determines the agonist specificity of V, receptors. FEBS Lett 362:19–23
Liu J, Wess J 1996 Different single receptor domains determine the distinct G protein coupling profiles of members of the vasopressin receptor family. J Biol Chem 271:8772–8778
Kojro E, Eich P, Gimpl G, Fahrenholz F 1993 Direct identification of an extracellular agonist binding site in the renal V, vasopressin receptor. Biochemistry 32:13537–13544
Chini B, Mouillac B, Ala Y, Balestre M-N, Trumpp-Kallmeyer S, Hoflack J, Elands J, Hibert M, Manning M, Jard S, Barberis C 1995 Try115 is the key residue for determining agonist selectivity in the V 1 a vasopressin receptor. EMBO J 14:2176–2182
Baldwin JM 1993 The probable arrangement of the helices in G protein-coupled receptors. EMBO J 12:1693–1703
Baldwin JM 1994 Structure and function of receptors coupled to G proteins. Current Opinion in Cell Biology 6:180–190
Postina R, Kojro E, Fahrenholz F 1996 Separate agonist and peptide antagonist binding sites of the oxytocin receptor defined by their transfer into the V2 vasopressin receptor. J Biol Chem 271:31593–31601
Mouillac B, Chini B, Balestre M-N, Elands J, Trumpp-Kallmeyer S, Hoflack J, Hibert M, Jard S, Barberis C 1995 The binding site of neuropeptide vasopressin V la receptor. J Biol Chem 270:25771–25777
Ku C-Y, Qian A, Wen Y, Anwer K, Sanborn BM 1995 Oxytocin stimulates myometrial guanosine triphosphate and phospholipase-C activities via coupling to Gaq,i,. Endocrinology 136:1509–1515
Elands J, Barberis C, Jard S, Tribollet E, Dreifuss J-J, Bankowski K, Manning M, Sawyer WH 1987 151-labelled d(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr-NH,9]OVT: A selective oxytocin receptor ligand. Eur J Pharmacol 147:197–207
Melin P, Trojnar J, Johansson B, Vilhardt H, Akerlund M 1986 Synthetic antagonists of the myometrial response to vasopressin and oxytocin. J Endocrinol 111:125–131
Hauksson A, Akerlund M, Melin P 1988 Uterine blood flow and myometrial activity at menstruation, and the action of vasopressin and synthetic antagonis. Br J Obstet Gynaecol 95:898–904
Kinsler VA, Thornton S, Ashford MLJ, Melin P, Smith SK 1996 The effect of the oxytocin antagonists F314 and F792 on the in vitro contractility of human myometrium. Br J Obstet Gynaecol 103:373–375
Kawarabayashi T, Kobayashi M, Akahane M, Ajisawa Y 1996 Comparison of in vitro and in vivo inhibitory effects of peptide and nonpeptide oxytocin antagonists on radioligand binding and uterine contractility of rats during pregnancy. Am J Obstet Gynecol 175:1348–1355
Suryanarayana S, Daunt DA, Zastrow MV, Kobilka BK 1991 A point mutation in the seventh hydrophobic domain of the a2 adrenergic receptor increases its affinity for a family of β receptor antagonists. J Biol Chem 266:15488–15492
Metcalf MA, McGuffin RW, Hamblin MW 1992 Conversion of the human 5-HTLDß serotonin receptor to the rat 5-HT1B ligand-binding phenotype by Thr355Asn site-directed mutagenesis. Biochem Pharmacol 44:1917–1920
Henderson R, Unwin PNT 1975 Three-dimensional model of purple membrane obtainen by electron microscopy. Nature 257:28–32
Schertler GFX, Villa C, Henderson R 1993 Projection structure of rhodopsin. Nature 362:770–772
Kojro E, Hackenberg M, Zsigo J, Fahrenholz F 1991 Identification and enzymatic deglycosylation of the myometrial oxytocin receptor using a radioiodinated photoreactive antagonist. J Biol Chem 266:21416–21421
Kojro E, Fahrenholz F 1995 Ligand-induced cleavage of the V2 vasopressin receptor by a plasma membrane metalloproteinase. J Biol Chem 270:6476–6481
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Postina, R., Kojro, E., Fahrenholz, F. (1998). Identification of Neurohypophysial Hormone Receptor Domains Involved in Ligand Binding and G Protein Coupling. In: Zingg, H.H., Bourque, C.W., Bichet, D.G. (eds) Vasopressin and Oxytocin. Advances in Experimental Medicine and Biology, vol 449. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4871-3_48
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4871-3_48
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7210-3
Online ISBN: 978-1-4615-4871-3
eBook Packages: Springer Book Archive